SABS

$3.80+0.12 (+3.26%)

After Hours$3.79-0.00 (-0.13%)· Last close May 6

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.

Overview Intraday ResearchPRO BacktestPRO Ask AIPRO TranscriptsPRO StatementsPRO